Share on facebook
Share on twitter
Share on linkedin

November 30, 2015: BioAegis Therapeutics Completes Development of Lyophilized Form of Plasma Gelsolin

Company Develops Temperature-Stable Lyophilized Protein

BOSTON, MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – November 30, 2015) BioAegis Therapeutics announces that it has successfully completed development of a lyophilized form of plasma gelsolin.
Lyophilization is the process of converting the bulk drug substance into a freeze-dried
form that can be stored in vials at room temperature. This eliminates the necessity of cold-chain storage, facilitating use in the clinic and minimizing storage and shipping costs.